Nautilus Biotech: "Next Generation Biopharmaceuticals (NGB)"
The NGB project associates Serono SA and Nautilus Biotech who will work together to develop next generation therapeutic proteins with improved biological, pharmacological and clinical profiles.
The partnership brings together a strong synergy between the two companies. Nautilus, which has proven proprietary technology for the improvement of bio-therapeutics, would design the new protein variants and validate them in vitro and in vivo. Serono would select protein variants created and validated by Nautilus and bring them through pre-clinical and clinical development to market.
"NGB is a strategic project for the two partners involved. It is expected to allow next generation therapeutic proteins, with improved profiles, to reach market and thus to improve patience compliance and quality of life," said Nautilus CEO Manuel Vega.
EUREKA is a pan-European network for market-oriented, industrial R&D. EUREKA supports the competitiveness of European companies through international collaboration, in creating links and networks of innovation. The objective is to bring high quality research and development efforts to the market and to use the multiplying effects of co-operation.
Using its proprietary technologies, Nautilus is strongly focused to improving human protein pharmaceuticals. Nautilus' pipeline is strategically focused on FDA-approved, marketed proteins, for which an improvement of their pharmacological profile would increase their already demonstrated clinical efficacy and market potential.
Additional information concerning Nautilus Biotech can be obtained from either www.nautilusbiotech.com or by e-mail: contact@nautilusbiotech.com .
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.